Matthew L. Sherman - Dec 12, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
EVP & Chief Medical Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Dec 12, 2023
Transactions value $
-$42,905
Form type
4
Date filed
12/14/2023, 04:05 PM
Previous filing
Oct 31, 2023
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award +8.24K +9.05% 99.3K Dec 12, 2023 Direct F1, F2
transaction DCPH Common Stock Sale -$42.9K -2.79K -2.81% $15.37 96.5K Dec 13, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs.
F2 Includes 434 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023.
F3 This sale was to cover tax liabilities in the vesting of RSUs.